Physician profile
Sunil Saini
NPI 1386648715
$6,010.21
in general payments reported to CMS, 2019-2025
25 companies · $409 in 2025
The $409 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,227 · 2020: $769 · 2021: $1,292 · 2022: $1,170 · 2023: $812 · 2024: $332 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,453 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,452.82 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,348.43 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $808.94 | 2019-2023 | Dupixent |
| Glaxosmithkline, LLC. | $759.25 | 2019-2023 | Nucala |
| Csl Behring | $748.92 | 2019-2025 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $360.14 | 2020-2023 | Hyqvia, Cuvitru |
| Shire North American Group INC | $226.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $222.32 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $199.02 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.53 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $152.84 | 2019-2022 | |
| Genentech USA, INC. | $136.93 | 2019-2023 | Xolair |
| Kaleo, INC. | $117.02 | 2019-2021 | |
| Pharming Healthcare, INC. | $107.14 | 2020 | |
| Pfizer INC. | $105.31 | 2019-2021 | |
| Optinose US, INC. | $94.92 | 2020-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $84.73 | 2023 | Xolair |
| Teva Pharmaceuticals USA, INC. | $71.77 | 2021 | |
| Alk-Abello, INC | $67.26 | 2020-2023 | Ragwitek, Grastek, Odactra |
| Incyte Corporation | $47.05 | 2021-2022 | |
| Octapharma USA, INC. | $43.34 | 2019 | |
| Biocryst US Sales Co., LLC | $29.59 | 2022 | |
| Depuy Synthes Sales INC. | $25.77 | 2021 | |
| Merck Sharp & Dohme LLC | $24.06 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.29 | 2022 | |
| Hikma Pharmaceuticals USA | $18.64 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Saini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.